Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03284424 · OUTCOME

Overall Survival (OS)

Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629) · Source last updated 2024-08-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Up to approximately 56 months

What was measured

OS was defined as the time from first dose of study treatment to death due to any cause. The OS for all participants is presented.

Analysis population: The analysis population consisted of all participants who received ≥1 dose of study treatment.

Groups in this outcome

Recurrent or Metastatic Cutaneous cSCC Cohort

Participants received pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 doses (approximately 24 months).

Locally Advanced Unresectable cSCC Cohort

Participants received pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 doses (approximately 24 months).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Recurrent or Metastatic Cutaneous cSCC Cohort105
Locally Advanced Unresectable cSCC Cohort54

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Recurrent or Metastatic Cutaneous cSCC Cohort23.8Not reported13.430.9Not reported
Locally Advanced Unresectable cSCC CohortNANot reported33.3NANA= Median and upper limit not reached at time of data cut-off due to insufficient number of participants with an event.
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        13.4
        upper Limit
        30.9
        value
        23.8
      2. comment
        NA= Median and upper limit not reached at time of data cut-off due to insufficient number of participants with an event.
        group Id
        OG001
        lower Limit
        33.3
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      105
    2. group Id
      OG001
      value
      54
    units
    Participants
description
OS was defined as the time from first dose of study treatment to death due to any cause. The OS for all participants is presented.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants received pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 doses (approximately 24 months).
    id
    OG000
    title
    Recurrent or Metastatic Cutaneous cSCC Cohort
  2. description
    Participants received pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 doses (approximately 24 months).
    id
    OG001
    title
    Locally Advanced Unresectable cSCC Cohort
param Type
MEDIAN
population Description
The analysis population consisted of all participants who received ≥1 dose of study treatment.
reporting Status
POSTED
time Frame
Up to approximately 56 months
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice